Hepatitis Monthly

Published by: Kowsar

Can HCV Core Ag Testing Replace the Routine Screening Assays in Patients on Hemodialysis?

Behzad Einollahi 1 , Neda Raeessi 2 , * and Fereshteh Raeessi 3
Authors Information
1 Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 Atherosclerosis Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
3 Clinical Research Center, Azad University of Pharmacy, Tehran, IR Iran
Article information
  • Hepatitis Monthly: July 01, 2014, 14 (7); e16371
  • Published Online: July 1, 2014
  • Article Type: Letter
  • Received: November 24, 2013
  • Accepted: November 29, 2013
  • DOI: 10.5812/hepatmon.16371

To Cite: Einollahi B, Raeessi N, Raeessi F. Can HCV Core Ag Testing Replace the Routine Screening Assays in Patients on Hemodialysis?, Hepat Mon. 2014 ; 14(7):e16371. doi: 10.5812/hepatmon.16371.

Copyright © 2014, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
  • 1. Moini M, Ziyaeyan M, Aghaei S, Sagheb MM, Taghavi SA, Moeini M, et al. Hepatitis C virus (HCV) Infection Rate among Seronegative Hemodialysis Patients Screened by Two Methods; HCV Core Antigen and Polymerase Chain Reaction. Hepat Mon. 2013; 13(6)[DOI][PubMed]
  • 2. Alavian SM. Diabetes, renal failure and hepatitis C infection: The puzzle should be attended more in future. Nephro Urol Mon.; 3(3): 153-4
  • 3. Alavian SM, Einollahi B, Hajarizadeh B, Bakhtiari S, Nafar M, Ahrabi S. Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. Nephrology (Carlton). 2003; 8(5): 256-60[PubMed]
  • 4. Elamin S, Abu-Aisha H. Prevention of hepatitis B virus and hepatitis C virus transmission in hemodialysis centers: review of current international recommendations. Arab J Nephrol Transplant. 2011; 4(1): 35-47[PubMed]
  • 5. Nemati E, Alavian SM, Taheri S, Moradi M, Pourfarziani V, Einollahi B. Hepatitis C virus infection among patients on hemodialysis: a report from a single center in Iran. Saudi J Kidney Dis Transpl. 2009; 20(1): 147-53[PubMed]
  • 6. Hajarizadeh B, Einollahi B, Alavian S, Nafar M. Prevalence of Hepatitis c virus (HCV) infection and related risk factors among Iranian patients on hemodialysis. Am J Infec Con. 2005; 33(5): 93-4[DOI]
  • 7. Li Cavoli G, Zagarrigo C, Schillaci O, Servillo F, Tralongo A, Coglitore M, et al. Hepatitis C virus core antigen test in monitoring of dialysis patients. Hepat Res Treat. 2012; 2012: 832021[DOI][PubMed]
  • 8. KDIGO clinical practice guideline for the diagnosis e, prevention, and treatment of Chronic Kidney Disease. Guideline 1: Detection and evaluation of HCV in CKD. Offic J Inter Soci Nephrol. 2008; 73(109): 10-9
  • 9. Veillon P, Payan C, Picchio G, Maniez-Montreuil M, Guntz P, Lunel F. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy. J Clin Microbiol. 2003; 41(7): 3212-20[PubMed]
  • 10. Kato A, Takita T, Furuhashi M, Fujimoto T, Suzuki H, Maruyama Y, et al. Association of HCV core antigen seropositivity with long-term mortality in patients on regular hemodialysis. Nephron Extra. 2012; 2(1): 76-86[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments